Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-02-03
2008-08-05
Balasubram, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S259310, C514S241000, C544S254000, C544S262000, C544S264000, C544S279000, C544S180000
Reexamination Certificate
active
07407962
ABSTRACT:
The present invention provides compounds that are inhibitors of protein kinase, particularly inhibitors of ERK2, GSK3, PKA, CDK2 protein kinases, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders.
REFERENCES:
patent: 1 422 218 (2004-05-01), None
patent: WO 02/064586 (2002-08-01), None
patent: WO 03/016275 (2003-02-01), None
patent: WO 03/093290 (2003-11-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Kim et al., Current Opinion in Genetics and Development,10, 508-514, 2000.
Fabbro et al. Pharmacology & therapeutics 93, 79-98, 2002.
Chang et al. “Role of cAMP-dependent pathway in eosinophil apoptosis and survival,” Cell. Immunology. 203(1):29-38, (2000).
Cline et al. “Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats,” Diabetes 51:2903-2910, (2002).
Frey et al. “TGF-beta regulation of mitogen-activated protein kinases in human breast cancer cells,” Cancer Letters 117(1):41-50, (1997).
Fukunaga et al. “Role of MAP kinase in neurons,” Molecular Neurobiology 16(1):79-95, (1998).
Hoshino et al. “Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors,” Oncogene 18:813-22, (1999).
Hu et al. “Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord,” J. Neurochemistry. 85(2):432-42, (2003).
Illenberger et al. “The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease,” Molecular Biology of The Cell 9(6):1495-512, (1998).
Kodama et al. “Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy,” Am. J. Physiol. Heart Circ. Physiol. 279(4):H1635-44, (2000).
Kortylewski et al “Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells,” Biochemical Journal 357(Pt 1):297-303, (2001).
Kyosseva et al. “Mitogen-activated protein kinases in schizophrenia,” Society of Biological Psychiatry 46(5):689-96, (1999).
Lee et al. “ICAM-I-induced expression of proinflammatory cytokines in astrocytes: involvement of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways,” The Journal of Immunology 165(8):4658-66, (2000).
Namura et al. “Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia,” Proc. Natl. Acad. Sci. U S A 98(20):11569-74, (2001).
Putz et al. “Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines,” Cancer Research 59(1):227-33, (1999).
Raghunandan et al. “Hyperphosphorylation of the cytoskeletal protein Tau by the MAP-kinase PK40erk2: regulation by prior phosphorylation with cAMP-dependent protein kinase A,” Biochemical and Biophysical Research Communications 215(3):1056-66, (1995).
Slevin et al. “Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke,” NeuroReport 11(12):2759-64, (2000).
Tack et al. “Autocrine activation of the IGF-1 signaling pathway in mesangial cells isolated from diabetic NOD mice,” Diabetes 51(1):182-8, (2002).
Aronov Alex
Hale Michael R.
Maltais Francois
Tang Qing
Balasubram Venkataraman
Pearson Daniel A.
Vertex Pharmaceuticals Incorporated
LandOfFree
Heteroaryl compounds useful as inhibitors or protein kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl compounds useful as inhibitors or protein kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl compounds useful as inhibitors or protein kinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4018887